Clinical data | |
---|---|
Trade names | Climacteron, Lactimex, Lactostat |
Other names | Testosterone enantate benziloylhydrazone; Testosterone 17β-enantate 3-benzilic acid hydrazone; TEBH; TEBAH; TEBaH |
Routes of administration | Intramuscular injection [1] [2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C40H52N2O4 |
Molar mass | 624.866 g·mol−1 |
3D model ( JSmol) | |
| |
|
Testosterone enantate benzilic acid hydrazone (TEBH), or testosterone 17β-enantate 3-benzilic acid hydrazone, is a synthetic, injected androgen/ anabolic steroid and an androgen ester – specifically, the C17β enantate ( heptanoate) ester and C3 benzilic acid hydrazone of testosterone. [1] [2] It was previously marketed in combination with estradiol benzoate and estradiol dienantate under the brand names Climacteron, Lactimex, and Lactostat. [2] [3] [4] Clinical studies have assessed this formulation. [5] [6] [7] [8] [9] [10] [11] [2] TEBH was first described in the scientific literature in 1959. [12] It is a very long-lasting prodrug of testosterone when administered in oil via intramuscular injection. [13] [14] [15]
Route | Medication | Major brand names | Form | Dosage |
---|---|---|---|---|
Oral | Testosterone undecanoate | Andriol, Jatenzo | Capsule | 40–80 mg 1x/1–2 days |
Methyltestosterone | Metandren, Estratest | Tablet | 0.5–10 mg/day | |
Fluoxymesterone | Halotestin | Tablet | 1–2.5 mg 1x/1–2 days | |
Normethandronea | Ginecoside | Tablet | 5 mg/day | |
Tibolone | Livial | Tablet | 1.25–2.5 mg/day | |
Prasterone ( DHEA)b | – | Tablet | 10–100 mg/day | |
Sublingual | Methyltestosterone | Metandren | Tablet | 0.25 mg/day |
Transdermal | Testosterone | Intrinsa | Patch | 150–300 μg/day |
AndroGel | Gel, cream | 1–10 mg/day | ||
Vaginal | Prasterone ( DHEA) | Intrarosa | Insert | 6.5 mg/day |
Injection | Testosterone propionatea | Testoviron | Oil solution | 25 mg 1x/1–2 weeks |
Testosterone enanthate | Delatestryl, Primodian Depot | Oil solution | 25–100 mg 1x/4–6 weeks | |
Testosterone cypionate | Depo-Testosterone, Depo-Testadiol | Oil solution | 25–100 mg 1x/4–6 weeks | |
Testosterone isobutyratea | Femandren M, Folivirin | Aqueous suspension | 25–50 mg 1x/4–6 weeks | |
Mixed testosterone esters | Climacterona | Oil solution | 150 mg 1x/4–8 weeks | |
Omnadren, Sustanon | Oil solution | 50–100 mg 1x/4–6 weeks | ||
Nandrolone decanoate | Deca-Durabolin | Oil solution | 25–50 mg 1x/6–12 weeks | |
Prasterone enanthatea | Gynodian Depot | Oil solution | 200 mg 1x/4–6 weeks | |
Implant | Testosterone | Testopel | Pellet | 50–100 mg 1x/3–6 months |
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template. |
Chemical synthesis of TEBH has been described. [16]
Clinical data | |
---|---|
Trade names | Climacteron, Lactimex, Lactostat |
Other names | Testosterone enantate benziloylhydrazone; Testosterone 17β-enantate 3-benzilic acid hydrazone; TEBH; TEBAH; TEBaH |
Routes of administration | Intramuscular injection [1] [2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C40H52N2O4 |
Molar mass | 624.866 g·mol−1 |
3D model ( JSmol) | |
| |
|
Testosterone enantate benzilic acid hydrazone (TEBH), or testosterone 17β-enantate 3-benzilic acid hydrazone, is a synthetic, injected androgen/ anabolic steroid and an androgen ester – specifically, the C17β enantate ( heptanoate) ester and C3 benzilic acid hydrazone of testosterone. [1] [2] It was previously marketed in combination with estradiol benzoate and estradiol dienantate under the brand names Climacteron, Lactimex, and Lactostat. [2] [3] [4] Clinical studies have assessed this formulation. [5] [6] [7] [8] [9] [10] [11] [2] TEBH was first described in the scientific literature in 1959. [12] It is a very long-lasting prodrug of testosterone when administered in oil via intramuscular injection. [13] [14] [15]
Route | Medication | Major brand names | Form | Dosage |
---|---|---|---|---|
Oral | Testosterone undecanoate | Andriol, Jatenzo | Capsule | 40–80 mg 1x/1–2 days |
Methyltestosterone | Metandren, Estratest | Tablet | 0.5–10 mg/day | |
Fluoxymesterone | Halotestin | Tablet | 1–2.5 mg 1x/1–2 days | |
Normethandronea | Ginecoside | Tablet | 5 mg/day | |
Tibolone | Livial | Tablet | 1.25–2.5 mg/day | |
Prasterone ( DHEA)b | – | Tablet | 10–100 mg/day | |
Sublingual | Methyltestosterone | Metandren | Tablet | 0.25 mg/day |
Transdermal | Testosterone | Intrinsa | Patch | 150–300 μg/day |
AndroGel | Gel, cream | 1–10 mg/day | ||
Vaginal | Prasterone ( DHEA) | Intrarosa | Insert | 6.5 mg/day |
Injection | Testosterone propionatea | Testoviron | Oil solution | 25 mg 1x/1–2 weeks |
Testosterone enanthate | Delatestryl, Primodian Depot | Oil solution | 25–100 mg 1x/4–6 weeks | |
Testosterone cypionate | Depo-Testosterone, Depo-Testadiol | Oil solution | 25–100 mg 1x/4–6 weeks | |
Testosterone isobutyratea | Femandren M, Folivirin | Aqueous suspension | 25–50 mg 1x/4–6 weeks | |
Mixed testosterone esters | Climacterona | Oil solution | 150 mg 1x/4–8 weeks | |
Omnadren, Sustanon | Oil solution | 50–100 mg 1x/4–6 weeks | ||
Nandrolone decanoate | Deca-Durabolin | Oil solution | 25–50 mg 1x/6–12 weeks | |
Prasterone enanthatea | Gynodian Depot | Oil solution | 200 mg 1x/4–6 weeks | |
Implant | Testosterone | Testopel | Pellet | 50–100 mg 1x/3–6 months |
Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: See template. |
Chemical synthesis of TEBH has been described. [16]